We found that the pathways affected by the dysregulation of the 20 most rewired genes in patient iCells correlate with the majority of the confirmed COVID-19 clinical symptoms, such as anosmia [46] (OLFM2 and REEP4), myopathy [47] (KLHL9), renal deficiency [48] (NUP85) and changes in the immune response [35] (CBX5 and CSTF2T). This evidence concerns the gene CBX5 and Anosmia.